Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Down 29.7% in December

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totaling 73,076 shares, a decrease of 29.7% from the December 15th total of 103,943 shares. Approximately 5.5% of the company’s shares are sold short. Based on an average trading volume of 86,065 shares, the short-interest ratio is presently 0.8 days. Based on an average trading volume of 86,065 shares, the short-interest ratio is presently 0.8 days. Approximately 5.5% of the company’s shares are sold short.

Galmed Pharmaceuticals Stock Down 1.6%

Galmed Pharmaceuticals stock traded down $0.01 during mid-day trading on Friday, reaching $0.77. 80,028 shares of the company traded hands, compared to its average volume of 75,579. Galmed Pharmaceuticals has a 52-week low of $0.73 and a 52-week high of $3.50. The firm’s 50 day moving average price is $0.93 and its 200 day moving average price is $1.33.

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Galmed Pharmaceuticals currently has a consensus rating of “Reduce”.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.